The Cooper Companies, Inc.
Aug 31, 2011

The Cooper Companies Announces Third Quarter 2011 Results

PLEASANTON, Calif., Aug. 31, 2011 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced financial results for the fiscal third quarter ended July 31, 2011.

Commenting on the results, Robert S. Weiss, Cooper's president and chief executive officer said, "I am pleased to report another strong quarter for the Company. We gained market share within CVI, posted solid margins in CVI and CSI, generated strong EPS, delivered improving free cash flow and significantly paid down debt. We are very encouraged by our business trends and believe we are well positioned to deliver strong operating results for the remainder of fiscal 2011."

Third Quarter GAAP Operating Highlights

Third Quarter CooperVision (CVI) GAAP Operating Highlights

        Constant Currency
  (In millions) % of CVI Revenue %chg %chg
  3Q11 3Q11 y/y y/y
Toric  $ 88.7 30% 17% 9%
Multifocal  19.7 6% 7% 1%
Single-use sphere  64.6 22% 21% 9%
Non single-use sphere, other  125.3 42% 24% 16%
Total  $ 298.3 100% 20% 11%
        Constant Currency
   (In millions)  % of CVI Revenue %chg %chg
   3Q11  3Q11 y/y y/y
Americas  $ 119.9 40% 7% 6%
EMEA  112.4 38% 25% 11%
Asia Pacific  66.0 22% 40% 24%
Total  $ 298.3 100% 20% 11%
        Constant Currency
   (In millions)  % of CVI Revenue %chg %chg
   3Q11  3Q11 y/y y/y
Proclear®  $ 80.7 27% 14% 5%
Silicone hydrogel  $ 91.9 31% 56% 47%

Third Quarter CooperSurgical (CSI) GAAP Operating Highlights

  (In millions) % of CSI Revenue %chg
  3Q11 3Q11 y/y
Office, other  $ 28.9 54% 5%
Surgical procedures  20.4 39% 29%
Fertility  3.8 7% 12%
Total  $ 53.1 100% 14%

2011 Guidance

The Company amends its full-year fiscal 2011 guidance and provides fiscal fourth quarter guidance. Guidance is summarized as follows:

  FY11 Guidance FY11 Guidance F4Q11 Guidance
  Old New New
Revenues (In millions)      
Total $1,280 - $1,300 $1,320 - $1,335 $350 - $365
CVI $1,080 - $1,095 $1,117 - $1,127 $300 - $310
CSI $200 - $205 $203 - $208 $50 - $55
GAAP $3.90 - $4.05 $3.67 - $3.72 $1.21 - $1.26
Non-GAAP* $4.00 - $4.15 $4.20 - $4.25 $1.19 - $1.24
Free Cash Flow (In millions) $190 - $210  $200 - $220 $46 - $66

* Excludes the impact of the 2009 CVI manufacturing restructuring plan, items related to acquisitions, costs related to the redemption of our senior notes and the reserve for inventory and return provisions related to the August 19, 2011 voluntary recall of certain lots of Avaira Toric contact lenses.  See "Reconciliation of Non-GAAP EPS to GAAP EPS" below.

Reconciliation of Non-GAAP EPS to GAAP EPS

To supplement our financial results and guidance presented on a GAAP basis, we use non-GAAP measures that we believe are helpful in understanding our results. The non-GAAP measures exclude inventory and return provisions related to the August 19, 2011 voluntary recall of certain lots of Avaira Toric contact lenses, costs related to acquisitions, including the reversal of the one-time gain on settlement of a preexisting relationship related to the acquisition of certain assets from Asahikasei Aime, restructuring costs and the redemption cost associated with the extinguishment of our senior notes on February 15, 2011. We exclude these items because we do not consider them reflective of our ongoing operating performance. Our non-GAAP financial results and guidance are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements and guidance prepared in accordance with GAAP. Management uses supplemental non-GAAP financial measures internally to understand, manage and evaluate our business and make operating decisions. These non-GAAP measures are among the factors management uses in planning and forecasting for future periods.

Non-GAAP net income and diluted EPS for the fiscal third quarter of 2011 excludes $18.1 million or 37 cents per share related to the aforementioned reserve for inventory and return provisions and the reversal of the one-time gain on settlement of a preexisting relationship.  Fiscal 2011 guidance excludes these costs along with costs related to the 2009 CooperVision manufacturing restructuring plan, items related to acquisitions and costs related to the redemption of our senior notes.

In the fiscal third quarter of 2011, we recognized a $14.2 million reserve for inventory and return provisions related to the August 19, 2011 voluntary recall of certain lots of Avaira Toric contact lenses. In the fiscal second quarter, we recognized a $16.5 million loss related to the redemption of the senior notes. The restructuring costs, primarily severance and costs associated with assets related to the closure of the Norfolk manufacturing plant, are recorded primarily in cost of sales. We completed the restructuring plan in the fiscal first quarter of 2011 and recognized total pre-tax restructuring charges under this plan of $23.1 million. We recognized $1.9 million in fiscal 2011, $16.1 million in fiscal 2010 and $5.1 million in fiscal 2009. In our fiscal third quarter we separately reported the reversal of the one-time gain on settlement of a preexisting relationship, initially reported in the fiscal first quarter, related to the acquisition of certain assets from Asahikasei Aime of $6.1 million in operating income. Also in our fiscal first quarter 2011, acquisition costs of $0.2 million, principally legal and other due diligence costs, were primarily recorded in selling, general and administrative expense. We believe it is useful for investors to understand the effects of these restructuring costs and acquisition items on our total operating results. 

We also report revenue growth using the non-GAAP financial measure of constant currency revenue. Management presents and refers to constant currency information so that revenue results may be evaluated excluding the effect of foreign currency rate fluctuations. To present this information, current period revenue for entities reporting in currencies other than United States dollars are converted into United States dollars at the average foreign exchange rates for the corresponding period in the prior year.

  Three Months Ended July 31,
  2011 GAAP  Adjustments  2011 Non-GAAP
Operating income  $ 45,887  $ 20,261  $ 66,148
Income before income taxes  $ 43,056  $ 20,261  $ 63,317
Provision for income taxes  $ 4,919  $ 2,191  $ 7,110
Net income  $ 38,137  $ 18,070  $ 56,207
Diluted EPS  $ 0.78  $ 0.37  $ 1.15
  Fiscal 2011 EPS Guidance
  2011 GAAP  Adjustments  2011 Non-GAAP
Diluted EPS $3.67 - $3.72 $0.53 $4.20 - $4.25

Conference Call and Webcast  

The Company will host a conference call today at 5:00 p.m. ET to discuss its third quarter 2011 financial results. The dial in number in the United States is +1-800-901-5231 and outside the United States is +1-617-786-2961. The passcode is 55243181. There will be a replay available approximately two hours after the call ends until Wednesday, September 7, 2011. The replay number in the United States is +1-888-286-8010 and outside the United States is +1-617-801-6888. The replay passcode is 48840701. This call will be broadcast live on our website at and at A transcript will be available on our website following the conference call. 

About The Cooper Companies

The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to serving the needs of the healthcare professional, improving the quality of life for its employees and customers and providing market leading products. Cooper's commitment to health and wellness is reflected through its corporate culture and global initiatives to promote healthy life choices for its employees. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting quality lenses for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Both companies provide superior product range and quality, along with friendly customer service and a drive to continually innovate. Cooper and CooperVision are headquartered in Pleasanton, CA, and CooperSurgical is headquartered in Trumbull, CT.

The Cooper Companies, Inc. logo is available at

Forward-Looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements which are other than statements of historical fact, including all statements regarding anticipated growth in our revenue, expected results of operations and integration of any acquisition are forward-looking. To identify these statements look for words like "believes," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. 

Among the factors that could cause our actual results and future actions to differ materially from those described in forward-looking statements are: adverse changes in the global or regional general business, political and economic conditions due to the current global economic downturn, including the impact of continuing uncertainty and instability of United States and international credit markets that may adversely affect the Company's or its customers' ability to meet future liquidity needs; costs and expenses related to the recall of a product, including those associated with the limited recall of the Avaira Toric contact lenses; limitations on sales following new product introductions due to poor market acceptance; new competitors, product innovations or technologies; a major disruption in the operations of our manufacturing, research and development or distribution facilities due to technological problems, natural disasters or other causes; disruptions in supplies of raw materials, particularly components used to manufacture our silicone hydrogel lenses; the impact of acquisitions or divestitures on revenues, earnings or margins; losses arising from future litigation, including the risk of adverse decisions or settlements related to litigation, or product recalls; interest rate and foreign currency exchange rate fluctuations; the requirement to provide for a significant liability or to write off, or accelerate depreciation on, a significant asset, including goodwill; changes in United States and foreign government regulations of the retail optical industry and of the healthcare industry generally; changes in tax laws or their interpretation and changes in effective tax rates; dilution to earnings per share from acquisitions or issuing stock and other events described in our Securities and Exchange Commission filings, including the "Business" and "Risk Factors" sections in the Company's Annual Report on Form 10-K for the fiscal year ended October 31, 2010, as such Risk Factors may be updated in quarterly filings. 

We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

Consolidated Condensed Balance Sheets
(In thousands)
   July 31,  October 31,
  2011 2010
Current assets:    
Cash and cash equivalents $7,872 $3,573
Trade receivables, net 218,416 197,490
Inventories 243,370 227,902
Deferred tax assets 33,061 28,828
Other current assets 40,917 33,547
Total current assets 543,636 491,340
Property, plant and equipment, net 601,094 593,887
Goodwill 1,270,300 1,261,976
Other intangibles, net 125,840 114,177
Deferred tax assets 27,208 23,072
Other assets 47,256 40,566
  $2,615,334 $2,525,018
Current liabilities:    
Short-term debt $38,735 $19,159
Other current liabilities 198,958 180,361
Total current liabilities 237,693 199,520
Long-term debt 406,485 591,977
Other liabilities 64,514 46,543
Deferred tax liabilities 18,964 20,202
Total liabilities 727,656 858,242
Stockholders' equity 1,887,678 1,666,776
  $2,615,334 $2,525,018
Consolidated Condensed Statements of Income
(In thousands, except earnings per share amounts)
   Three Months Ended  Nine Months Ended
   July 31,   July 31,
  2011 2010 2011 2010
Net sales  $351,396 $295,635 $969,926 $845,165
Cost of sales 148,594 119,649 388,755 355,923
Gross profit 202,802 175,986 581,171 489,242
Selling, general and administrative expense 133,617 111,265 373,453 323,183
Research and development expense 11,725 8,588 31,843 24,788
Restructuring costs -- 14 -- 424
Settlement of preexisting relationship 6,080 -- -- --
Amortization of intangibles 5,493 4,723 14,940 13,439
Operating income 45,887 51,396 160,935 127,408
Interest expense 3,217 8,729 14,436 28,684
Loss on extinguishment of debt -- -- 16,487 --
Litigation settlement charge -- -- -- 27,000
Other income (expense), net 386 985 (128) (1,174)
Income before income taxes 43,056 43,652 129,884 70,550
Provision for income taxes 4,919 3,925 11,092 5,945
Net income $38,137 $39,727 $118,792 $64,605
Diluted earnings per share $0.78 $0.86 $2.46 $1.40
Number of shares used to compute earnings per share 49,009 46,402 48,362 46,232

Soft Contact Lens Revenue Update

Worldwide Market vs. CooperVision (Constant Currency)

The data below is extracted from a compilation of industry participants' revenue by the Contact Lens Institute (CLI), an independent market research firm. This data is compiled using gross product sales at foreign exchange rates set by CLI. It therefore excludes items such as discounts, rebates, currency hedges and freight reimbursements.

Worldwide Manufacturers' Soft Contact Lens Revenue        
(U.S. dollars in millions; constant currency; unaudited)        
  Calendar 2Q11 Trailing Twelve Months
    Market CVI   Market CVI
  Market Change Change Market Change Change
Sales by Category            
Spheres  $ 1,324 3% 10%  $ 5,182 4% 8%
Torics  323 8% 10%  1,249 9% 14%
Multifocal  82 5% 1%  314 10%  (1%)
WW Soft Contact Lenses  $ 1,729 4% 9%  $ 6,745 5% 9%
Sales by Modality            
Single Use  $ 650 8% 12%  $ 2,473 8% 10%
Other  1,079 2% 9%  4,272 3% 8%
WW Soft Contact Lenses  $ 1,729 4% 9%  $ 6,745 5% 9%
Sales by Material            
Hydrogel  $ 993  (0%)  (2%)  $ 3,948  (2%)  (4%)
Silicone Hydrogel  736 11% 47%  2,797 16% 60%
WW Soft Contact Lenses  $ 1,729 4% 9%  $ 6,745 5% 9%
Sales by Geography            
Americas   $ 662 6% 7%  $ 2,562 6% 9%
EMEA  506 4% 12%  1,961 7% 10%
Asia Pacific   561 2% 10%  2,222 2% 5%
WW Soft Contact Lenses  $ 1,729 4% 9%  $ 6,745 5% 9%
United States  $ 570 7% 8%  $ 2,189 6% 10%
International  1,159 3% 10%  4,556 4% 8%
WW Soft Contact Lenses  $ 1,729 4% 9%  $ 6,745 5% 9%


CONTACT: Albert G. White, III

         VP, Investor Relations, Treasurer & Chief Strategic Officer

         Kim Duncan

         Director, Investor Relations


The Cooper Companies, Inc. Logo

Source: The Cooper Companies, Inc.

News Provided by Acquire Media